Education
About Us
Working with TipRanks
Follow Us
Jaguar Animal Health (JAGX)
NASDAQ:JAGX
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-7.13Last Year’s EPS
-101Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -4.70%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive breakthroughs in medical research with crofelemer and ongoing financial challenges. While there were significant advancements in clinical trials and potential regulatory approvals, the financial metrics showed a decline in revenue and increased losses.Company Guidance
During the May 15, 2025, investor webcast, Jaguar Health's CEO, Lisa Conte, discussed several key metrics and initiatives. Notably, dispensed prescriptions for Mytesi, a treatment for HIV-related diarrhea, increased by approximately 2% in Q1 2025 compared to Q1 2024, despite a decrease in net revenue. Initial proof-of-concept results for crofelemer showed a reduction in total parenteral nutrition (TPN) by up to 27% in the first MVID patient, highlighting its potential impact on rare diseases. Jaguar's rare disease programs, in development for nearly eight years, include ongoing trials for MVID and short bowel syndrome, with results expected through 2025 and 2026. Financially, the company reported a 6% decrease in net revenue for Q1 2025 versus Q1 2024, while non-GAAP recurring EBITDA reflected a net loss of $9.7 million. Additionally, Jaguar is exploring expedited regulatory pathways and potential business development opportunities to enhance stakeholder value.Increased Prescriptions for Mytesi
Dispensed prescriptions for Mytesi increased by approximately 2% in Q1 2025 compared to Q1 2024, indicating increased demand and treatment for HIV-related diarrhea.
Groundbreaking Results for Crofelemer
Initial proof-of-concept results showed that crofelemer reduced TPN by up to 27% in the first MVID patient and by up to 12.5% in the first pediatric SBS patient, which is significant for patients with intestinal failure.
Significant Results in Breast Cancer Patients
In the OnTarget study, crofelemer achieved statistically significant results in breast cancer patients, and these findings are being presented at notable conferences.
Exploration of Regulatory Pathways for Expedited Approval
Jaguar is exploring expedited regulatory approval pathways for crofelemer in treating MVID and short bowel syndrome, with orphan designation potentially allowing for faster approvals.
---
JAGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JAGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $6.17 | $5.50 | -10.86% |
Mar 31, 2025 | $5.00 | $4.76 | -4.80% |
Nov 13, 2024 | $27.25 | $24.69 | -9.39% |
Aug 13, 2024 | $30.00 | $26.75 | -10.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Jaguar Animal Health (JAGX) report earnings?
Jaguar Animal Health (JAGX) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Jaguar Animal Health (JAGX) earnings time?
Jaguar Animal Health (JAGX) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JAGX EPS forecast?
JAGX EPS forecast for the fiscal quarter 2025 (Q2) is -7.13.
---